Regorafenib

/Tag:Regorafenib

Regorafenib-Related Hand-Foot Skin Reaction

A recent comprehensive review of the literature of the PubMed database and of the clinical experiences of oncologists and dermatologists concerning patients with regorafenib (Stivarga) related hand-foot skin reaction (HFSR) was published in the Annals [...]

By | 2015-06-25T13:24:29+00:00 June 26th, 2015|News, Side Effects|

Phase II Clinical Trial in Australia

A Phase II clinical trial comparing Imatinib alternated with Regorafenib to Imatinib alone is currently underway and recruiting in Australia. The trial, sponsored by the Australasian Gastro-Intestinal Trials Group (http://agitg.org.au), looks to examine the feasibility [...]

By | 2015-03-11T15:50:52+00:00 March 12th, 2015|Clinical Trials, Global, News|

UK Pulls Stivarga From Cancer Drug Fund Endangering GIST Patients

The National Health Service (NHS) in the United Kingdom has announced plans to halt funding through the Cancer Drug Fund for regorafenib (Stivarga), thereby preventing GIST patients from having access to this life-saving medication.We at [...]

By | 2018-09-10T09:36:55+00:00 January 29th, 2015|Advocacy, News, Stivarga|

Stivarga Approved for Canadian GIST Patients

Health Canada has expanded approval for the use of Stivarga to fight Gastrointestinal Stromal Tumours (GIST), according to an article from CNW. Bayer announced that Stivarga will now be available for treatment of adult patients with [...]

By | 2014-04-17T13:24:36+00:00 October 18th, 2013|Drug Treatment, News, Stivarga|

Stivarga becomes first FDA-approved third-line drug treatment for GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.

By | 2014-09-14T11:30:49+00:00 April 1st, 2013|Drug Treatment, News, Side Effects, Stivarga|

FDA approves Stivarga for advanced GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.

By | 2014-09-14T11:31:07+00:00 February 25th, 2013|Clinical Trials, Drug Treatment, News, Stivarga|

LRG & colleagues make their mark on 17th annual CTOS meeting in Prague

Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.

By | 2014-09-14T11:31:32+00:00 February 1st, 2013|Events, News|

Recent Posts

Upcoming Events

  1. Sarcoma & GIST: Education Symposium

    September 29 @ 9:00 AM - 2:45 PM
  2. Michigan GDOL 2018

    Michigan GDOL 2018

    October 27 @ 8:00 AM - 3:00 PM
  3. NTFC

    Night to Fight Cancer

    November 7 @ 6:00 PM - 11:00 PM